Skip To Main Content
Dolorès Pourette on Muck Rack

Dolorès Pourette

As seen in: The Conversation, Biomed Central (BMC), The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Dolorès Pourette’s profile

Articles by Dolorès Pourette

À Mayotte, les évacuations sanitaires sont un maillon essentiel de l’accès aux soins

|
By Dolorès Pourette, Chargée de recherche
| The Conversation Verified
La situation sanitaire à Mayotte après le passage du cyclone Chido met en lumière les grandes vulnérabilités du système de soin sur l’île. Ainsi, même hors situations d’urgence, le dispositif d’évacuations sanitaires français EVASAN tente de suppléer au manque criant de structures de soin et de personnel médical dans ce département français pour assurer l’accès aux soins de la population.
Open in Who Shared Issue with article?

Viral hepatitis in sub-Saharan Africa

|
By Yusuke Shimakawa, Dolorès Pourette, Louis Bainilago, Catherine Enel
| The Lancet Verified
Executive Summary In 2016, WHO adopted a strategy for the elimination of viral hepatitis by 2030. Sub-Saharan Africa carries a substantial portion of the global burden of viral hepatitis, particularly chronic hepatitis B and hepatitis C. Countries in the region face unique challenges, with the development of elimination strategies often hindered by a lack of good quality data.
Open in Who Shared Issue with article?

Improving communication about viral hepatitis in Africa

|
By Yusuke Shimakawa, Dolorès Pourette, IRD-Université Paris Descartes
| The Lancet Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Viral hepatitis is the seventh leading cause of death worldwide.1 By 2030, WHO's elimination strategy2 seeks to reduce mortality from chronic infection with hepatitis B and C viruses by 65%. To achieve this goal, it is essential to scale up antiviral treatment programmes in low-income and middle-income countries, where most deaths due to hepatitis occur.
Open in Who Shared Issue with article?
Show More